Cerenis Therapeutics Holding SA announced the creation of its scientific advisory board in Oncology with five key appointments Briggs Morrison, Mark Frohlich, Aurélien Marabelle, Robert Schneider and Robert J. Spiegel. Briggs Morrison will serve as the Chairman of the SAB. Dr. Morrison has overseen the development of numerous biopharmaceutical products in multiple therapeutic areas, from First-In-Human trials through to global regulatory approvals. He is currently a Board member of private companies Oncorus and Repare Therapeutics, and is an advisor to a number of other private biotechnology companies. Dr. Mark Frohlich has been involved in the development of cellular immunotherapies for cancer for more than 15 years. He was recently EVP of Portfolio Strategy at Juno Therapeutics. Dr. Aurélien Marabelle's clinical director of the Cancer Immunotherapy Program at Gustave Roussy cancer center. Dr. Robert Schneider is associate director of the NYU cancer institute, Director of Translational Cancer Research, and Co-director of the Breast Cancer Research Program at NYU School of Medicine. Dr. Spiegel has over 30 years of extensive R&D and operational experience in biopharmaceuticals including Big Pharma, biotech, and academic startups as well as interactions advising venture capital and private equity.